The role of new cytotoxic agents for the treatment of metastatic breast cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Chemotherapy with agents such as the anthracyclines and the taxanes remains a mainstay of breast cancer treatment, however improvement on these therapies is clearly needed. It is important to achieve a greater clinical benefit not only in patients who have developed resistance to these agents, but also in key patient sub-populations who have the worst prognosis. The papers in this supplement do not just highlight the problems faced when treating these patient groups, but provide some hope for the improvements we can expect from future therapies, including new cytotoxics.

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalEuropean Journal of Cancer, Supplement
Volume7
Issue number1
DOIs
Publication statusPublished - Mar 2009

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'The role of new cytotoxic agents for the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this